ANI Pharmaceuticals Inc
ANIP
Market Cap$1.35B
Close$
$-52.61
180.4% downside
Current Fair Value
180.4% downsideOvervalued by 180.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.35 Billion |
|---|---|
| Enterprise Value | $1.42 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $0.94 |
| Beta | 0.53 |
| Outstanding Shares | 20,980,307 |
| Avg 30 Day Volume | 152,479 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 78.99 |
|---|---|
| PEG | -60.2 |
| Price to Sales | 2.84 |
| Price to Book Ratio | 3.27 |
| Enterprise Value to Revenue | 2.92 |
| Enterprise Value to EBIT | 28.66 |
| Enterprise Value to Net Income | 82 |
| Total Debt to Enterprise | 0.2 |
| Debt to Equity | 0.66 |
Revenue Sources
No data
ESG Score
No data
About ANI Pharmaceuticals Inc
CEO: Patrick Walsh ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include ...